|Part of a series on|
A vaccine is a biological preparation that provides active acquired immunity to a particular infectious disease. A vaccine typically contains an agent that resembles a disease-causing microorganism and is often made from weakened or killed forms of the microbe, its toxins, or one of its surface proteins. The agent stimulates the body's immune system to recognize the agent as a threat, destroy it, and to further recognize and destroy any of the microorganisms associated with that agent that it may encounter in the future. Vaccines can be prophylactic (to prevent or ameliorate the effects of a future infection by a natural or "wild" pathogen), or therapeutic (to fight a disease that has already occurred, such as cancer). Some vaccines offer full sterilizing immunity, in which infection is prevented completely.
The administration of vaccines is called vaccination. Vaccination is the most effective method of preventing infectious diseases; widespread immunity due to vaccination is largely responsible for the worldwide eradication of smallpox and the restriction of diseases such as polio, measles, and tetanus from much of the world. The effectiveness of vaccination has been widely studied and verified; for example, vaccines that have proven effective include the influenza vaccine, the HPV vaccine, and the chickenpox vaccine. The World Health Organization (WHO) reports that licensed vaccines are currently available for twenty-five different preventable infections.
The terms vaccine and vaccination are derived from Variolae vaccinae (smallpox of the cow), the term devised by Edward Jenner (who both developed the concept of vaccines and created the first vaccine) to denote cowpox. He used the phrase in 1798 for the long title of his Inquiry into the Variolae vaccinae Known as the Cow Pox, in which he described the protective effect of cowpox against smallpox. In 1881, to honor Jenner, Louis Pasteur proposed that the terms should be extended to cover the new protective inoculations then being developed. The science of vaccine development and production is termed vaccinology.
There is overwhelming scientific consensus that vaccines are a very safe and effective way to fight and eradicate infectious diseases. The immune system recognizes vaccine agents as foreign, destroys them, and "remembers" them. When the virulent version of an agent is encountered, the body recognizes the protein coat on the virus, and thus is prepared to respond, by first neutralizing the target agent before it can enter cells, and secondly by recognizing and destroying infected cells before that agent can multiply to vast numbers.
Limitations to their effectiveness, nevertheless, exist. Sometimes, protection fails because of vaccine-related failures such as failures in vaccine attenuation, vaccination regimes or administration or host-related failure due to the host's immune system simply does not respond adequately or at all. Lack of response commonly results from genetics, immune status, age, health or nutritional status. It also might fail for genetic reasons if the host's immune system includes no strains of B cells that can generate antibodies suited to reacting effectively and binding to the antigens associated with the pathogen.
Even if the host does develop antibodies, protection might not be adequate; immunity might develop too slowly to be effective in time, the antibodies might not disable the pathogen completely, or there might be multiple strains of the pathogen, not all of which are equally susceptible to the immune reaction. However, even a partial, late, or weak immunity, such as a one resulting from cross-immunity to a strain other than the target strain, may mitigate an infection, resulting in a lower mortality rate, lower morbidity, and faster recovery.
The efficacy or performance of the vaccine is dependent on several factors:
- the disease itself (for some diseases vaccination performs better than for others)
- the strain of vaccine (some vaccines are specific to, or at least most effective against, particular strains of the disease)
- whether the vaccination schedule has been properly observed.
- idiosyncratic response to vaccination; some individuals are "non-responders" to certain vaccines, meaning that they do not generate antibodies even after being vaccinated correctly.
- assorted factors such as ethnicity, age, or genetic predisposition.
Important considerations in an effective vaccination program:
- careful modeling to anticipate the effect that an immunization campaign will have on the epidemiology of the disease in the medium to long term
- ongoing surveillance for the relevant disease following introduction of a new vaccine
- maintenance of high immunization rates, even when a disease has become rare
In 1958, there were 763,094 cases of measles in the United States; 552 deaths resulted. After the introduction of new vaccines, the number of cases dropped to fewer than 150 per year (median of 56). In early 2008, there were 64 suspected cases of measles. Fifty-four of those infections were associated with importation from another country, although only thirteen percent were actually acquired outside the United States; 63 of the 64 individuals either had never been vaccinated against measles or were uncertain whether they had been vaccinated.
Vaccines led to the eradication of smallpox, one of the most contagious and deadly diseases in humans. Other diseases such as rubella, polio, measles, mumps, chickenpox, and typhoid are nowhere near as common as they were a hundred years ago thanks to widespread vaccination programs. As long as the vast majority of people are vaccinated, it is much more difficult for an outbreak of disease to occur, let alone spread. This effect is called herd immunity. Polio, which is transmitted only among humans, is targeted by an extensive eradication campaign that has seen endemic polio restricted to only parts of three countries (Afghanistan, Nigeria, and Pakistan). However, the difficulty of reaching all children as well as cultural misunderstandings have caused the anticipated eradication date to be missed several times.
Vaccines also help prevent the development of antibiotic resistance. For example, by greatly reducing the incidence of pneumonia caused by Streptococcus pneumoniae, vaccine programs have greatly reduced the prevalence of infections resistant to penicillin or other first-line antibiotics.
The measles vaccine is estimated to prevent a million deaths every year.
Vaccinations given to children, adolescents, or adults are generally safe. Adverse effects, if any, are generally mild. The rate of side effects depends on the vaccine in question. Some common side effects include fever, pain around the injection site, and muscle aches. Additionally, some individuals may be allergic to ingredients in the vaccine. MMR vaccine is rarely associated with febrile seizures.
Host-("vaccinee")-related determinants that render a person susceptible to infection, such as genetics, health status (underlying disease, nutrition, pregnancy, sensitivities or allergies), immune competence, age, and economic impact or cultural environment can be primary or secondary factors affecting the severity of infection and response to a vaccine. Elderly (above age 60), allergen-hypersensitive, and obese people have susceptibility to compromised immunogenicity, which prevents or inhibits vaccine effectiveness, possibly requiring separate vaccine technologies for these specific populations or repetitive booster vaccinations to limit virus transmission.
Severe side effects are extremely rare. Varicella vaccine is rarely associated with complications in immunodeficient individuals, and rotavirus vaccines are moderately associated with intussusception.
At least 19 countries have no-fault compensation programs to provide compensation for those suffering severe adverse effects of vaccination. The United States’ program is known as the National Childhood Vaccine Injury Act, and the United Kingdom employs the Vaccine Damage Payment.
Vaccines typically contain dead or inactivated organisms or purified products derived from them. There are several types of vaccines in use. These represent different strategies used to try to reduce the risk of illness while retaining the ability to induce a beneficial immune response. The subgroup of genetic vaccines encompass DNA vaccines, RNA vaccines and viral vector vaccines.
Some vaccines contain live, attenuated microorganisms. Many of these are active viruses that have been cultivated under conditions that disable their virulent properties, or that use closely related but less dangerous organisms to produce a broad immune response. Although most attenuated vaccines are viral, some are bacterial in nature. Examples include the viral diseases yellow fever, measles, mumps, and rubella, and the bacterial disease typhoid. The live Mycobacterium tuberculosis vaccine developed by Calmette and Guérin is not made of a contagious strain but contains a virulently modified strain called "BCG" used to elicit an immune response to the vaccine. The live attenuated vaccine containing strain Yersinia pestis EV is used for plague immunization. Attenuated vaccines have some advantages and disadvantages. Attenuated, or live, weakened, vaccines typically provoke more durable immunological responses. But they may not be safe for use in immunocompromised individuals, and on rare occasions mutate to a virulent form and cause disease.
Some vaccines contain inactivated, but previously virulent, micro-organisms that have been destroyed with chemicals, heat, or radiation – "ghosts", with intact but empty bacterial cell envelopes. They are considered an intermediate phase between the inactivated and attenuated vaccines. Examples include IPV (polio vaccine), hepatitis A vaccine, rabies vaccine and most influenza vaccines.
Toxoid vaccines are made from inactivated toxic compounds that cause illness rather than the micro-organism. Examples of toxoid-based vaccines include tetanus and diphtheria. Not all toxoids are for micro-organisms; for example, Crotalus atrox toxoid is used to vaccinate dogs against rattlesnake bites.
Rather than introducing an inactivated or attenuated micro-organism to an immune system (which would constitute a "whole-agent" vaccine), a subunit vaccine uses a fragment of it to create an immune response. One example is the subunit vaccine against hepatitis B, which is composed of only the surface proteins of the virus (previously extracted from the blood serum of chronically infected patients but now produced by recombination of the viral genes into yeast). Another example is edible algae vaccines, such as the virus-like particle (VLP) vaccine against human papillomavirus (HPV), which is composed of the viral major capsid protein. Another example is the hemagglutinin and neuraminidase subunits of the influenza virus. A subunit vaccine is being used for plague immunization.
Certain bacteria have a polysaccharide outer coat that is poorly immunogenic. By linking these outer coats to proteins (e.g., toxins), the immune system can be led to recognize the polysaccharide as if it were a protein antigen. This approach is used in the Haemophilus influenzae type B vaccine.
Outer membrane vesicle
Outer membrane vesicles (OMVs) are naturally immunogenic and can be manipulated to produce potent vaccines. The best known OMV vaccines are those developed for serotype B meningococcal disease.
Heterologous vaccines also known as "Jennerian vaccines", are vaccines that are pathogens of other animals that either do not cause disease or cause mild disease in the organism being treated. The classic example is Jenner's use of cowpox to protect against smallpox. A current example is the use of BCG vaccine made from Mycobacterium bovis to protect against tuberculosis.
An mRNA vaccine (or RNA vaccine) is a novel type of vaccine which is composed of the nucleic acid RNA, packaged within a vector such as lipid nanoparticles. Among the COVID-19 vaccines are a number of RNA vaccines under development to combat the COVID-19 pandemic and some have received emergency use authorization in some countries. For example, the Pfizer-BioNTech and Moderna mRNA vaccines have emergency use authorization in the US.
Many innovative vaccines are also in development and use.
- Dendritic cell vaccines combine dendritic cells with antigens to present the antigens to the body's white blood cells, thus stimulating an immune reaction. These vaccines have shown some positive preliminary results for treating brain tumors and are also tested in malignant melanoma.
- DNA vaccination – The proposed mechanism is the insertion and expression of viral or bacterial DNA in human or animal cells (enhanced by the use of electroporation), triggering immune system recognition. Some cells of the immune system that recognize the proteins expressed will mount an attack against these proteins and cells expressing them. Because these cells live for a very long time, if the pathogen that normally expresses these proteins is encountered at a later time, they will be attacked instantly by the immune system. One potential advantage of DNA vaccines is that they are very easy to produce and store.
- Recombinant vector – by combining the physiology of one micro-organism and the DNA of another, immunity can be created against diseases that have complex infection processes. An example is the RVSV-ZEBOV vaccine licensed to Merck that is being used in 2018 to combat ebola in Congo.
- T-cell receptor peptide vaccines are under development for several diseases using models of Valley Fever, stomatitis, and atopic dermatitis. These peptides have been shown to modulate cytokine production and improve cell-mediated immunity.
- Targeting of identified bacterial proteins that are involved in complement inhibition would neutralize the key bacterial virulence mechanism.
- The use of plasmids has been validated in preclinical studies as a protective vaccine strategy for cancer and infectious diseases. However, in human studies, this approach has failed to provide clinically relevant benefit. The overall efficacy of plasmid DNA immunization depends on increasing the plasmid's immunogenicity while also correcting for factors involved in the specific activation of immune effector cells.
- Bacterial vector – Similar in principle to viral vector vaccines, but using bacteria instead.
- Antigen-presenting cell
While most vaccines are created using inactivated or attenuated compounds from micro-organisms, synthetic vaccines are composed mainly or wholly of synthetic peptides, carbohydrates, or antigens.
Vaccines may be monovalent (also called univalent) or multivalent (also called polyvalent). A monovalent vaccine is designed to immunize against a single antigen or single microorganism. A multivalent or polyvalent vaccine is designed to immunize against two or more strains of the same microorganism, or against two or more microorganisms. The valency of a multivalent vaccine may be denoted with a Greek or Latin prefix (e.g., tetravalent or quadrivalent). In certain cases, a monovalent vaccine may be preferable for rapidly developing a strong immune response.
When two or more vaccines are mixed in the same formulation, the two vaccines can interfere. This most frequently occurs with live attenuated vaccines, where one of the vaccine components is more robust than the others and suppresses the growth and immune response to the other components. This phenomenon was first noted in the trivalent Sabin polio vaccine, where the amount of serotype 2 virus in the vaccine had to be reduced to stop it from interfering with the "take" of the serotype 1 and 3 viruses in the vaccine. This phenomenon has also been found to be a problem with the dengue vaccines currently being researched,[when?] where the DEN-3 serotype was found to predominate and suppress the response to DEN-1, −2 and −4 serotypes.
Vaccines typically contain one or more adjuvants, used to boost the immune response. Tetanus toxoid, for instance, is usually adsorbed onto alum. This presents the antigen in such a way as to produce a greater action than the simple aqueous tetanus toxoid. People who have an adverse reaction to adsorbed tetanus toxoid may be given the simple vaccine when the time comes for a booster.
In the preparation for the 1990 Persian Gulf campaign, the whole cell pertussis vaccine was used as an adjuvant for anthrax vaccine. This produces a more rapid immune response than giving only the anthrax vaccine, which is of some benefit if exposure might be imminent.
Vaccines may also contain preservatives to prevent contamination with bacteria or fungi. Until recent years, the preservative thiomersal (a.k.a. Thimerosal in the US and Japan) was used in many vaccines that did not contain live viruses. As of 2005, the only childhood vaccine in the U.S. that contains thiomersal in greater than trace amounts is the influenza vaccine, which is currently recommended only for children with certain risk factors. Single-dose influenza vaccines supplied in the UK do not list thiomersal in the ingredients. Preservatives may be used at various stages of the production of vaccines, and the most sophisticated methods of measurement might detect traces of them in the finished product, as they may in the environment and population as a whole.
Many vaccines need preservatives to prevent serious adverse effects such as Staphylococcus infection, which in one 1928 incident killed 12 of 21 children inoculated with a diphtheria vaccine that lacked a preservative. Several preservatives are available, including thiomersal, phenoxyethanol, and formaldehyde. Thiomersal is more effective against bacteria, has a better shelf-life, and improves vaccine stability, potency, and safety; but, in the U.S., the European Union, and a few other affluent countries, it is no longer used as a preservative in childhood vaccines, as a precautionary measure due to its mercury content. Although controversial claims have been made that thiomersal contributes to autism, no convincing scientific evidence supports these claims. Furthermore, a 10–11-year study of 657,461 children found that the MMR vaccine does not cause autism and actually reduced the risk of autism by seven percent.
- Aluminum salts or gels are added as adjuvants. Adjuvants are added to promote an earlier, more potent response, and more persistent immune response to the vaccine; they allow for a lower vaccine dosage.
- Antibiotics are added to some vaccines to prevent the growth of bacteria during production and storage of the vaccine.
- Egg protein is present in the influenza vaccine and yellow fever vaccine as they are prepared using chicken eggs. Other proteins may be present.
- Formaldehyde is used to inactivate bacterial products for toxoid vaccines. Formaldehyde is also used to inactivate unwanted viruses and kill bacteria that might contaminate the vaccine during production.
- Monosodium glutamate (MSG) and 2-phenoxyethanol are used as stabilizers in a few vaccines to help the vaccine remain unchanged when the vaccine is exposed to heat, light, acidity, or humidity.
- Thiomersal is a mercury-containing antimicrobial that is added to vials of vaccines that contain more than one dose to prevent contamination and growth of potentially harmful bacteria. Due to the controversy surrounding thiomersal, it has been removed from most vaccines except multi-use influenza, where it was reduced to levels so that a single dose contained less than a microgram of mercury, a level similar to eating ten grams of canned tuna.
Various fairly standardized abbreviations for vaccine names have developed, although the standardization is by no means centralized or global. For example, the vaccine names used in the United States have well-established abbreviations that are also widely known and used elsewhere. An extensive list of them provided in a sortable table and freely accessible is available at a US Centers for Disease Control and Prevention web page. The page explains that "The abbreviations [in] this table (Column 3) were standardized jointly by staff of the Centers for Disease Control and Prevention, ACIP Work Groups, the editor of the Morbidity and Mortality Weekly Report (MMWR), the editor of Epidemiology and Prevention of Vaccine-Preventable Diseases (the Pink Book), ACIP members, and liaison organizations to the ACIP."
Some examples are "DTaP" for diphtheria and tetanus toxoids and acellular pertussis vaccine, "DT" for diphtheria and tetanus toxoids, and "Td" for tetanus and diphtheria toxoids. At its page on tetanus vaccination, the CDC further explains that "Upper-case letters in these abbreviations denote full-strength doses of diphtheria (D) and tetanus (T) toxoids and pertussis (P) vaccine. Lower-case "d" and "p" denote reduced doses of diphtheria and pertussis used in the adolescent/adult-formulations. The 'a' in DTaP and Tdap stands for 'acellular', meaning that the pertussis component contains only a part of the pertussis organism."
Another list of established vaccine abbreviations is at the CDC's page called "Vaccine Acronyms and Abbreviations", with abbreviations used on U.S. immunization records. The United States Adopted Name system has some conventions for the word order of vaccine names, placing head nouns first and adjectives postpositively. This is why the USAN for "OPV" is "poliovirus vaccine live oral" rather than "oral poliovirus vaccine".
A vaccine licensure occurs after the successful conclusion of the development cycle and further the clinical trials and other programs involved through Phases I–III demonstrating safety, immunoactivity, immunogenetic safety at a given specific dose, proven effectiveness in preventing infection for target populations, and enduring preventive effect (time endurance or need for revaccination must be estimated). Because preventive vaccines are predominantly evaluated in healthy population cohorts and distributed among the general population, a high standard of safety is required. As part of a multinational licensing of a vaccine, the World Health Organization Expert Committee on Biological Standardization developed guidelines of international standards for manufacturing and quality control of vaccines, a process intended as a platform for national regulatory agencies to apply for their own licensing process. Vaccine manufacturers do not receive licensing until a complete clinical cycle of development and trials proves the vaccine is safe and has long-term effectiveness, following scientific review by a multinational or national regulatory organization, such as the European Medicines Agency (EMA) or the US Food and Drug Administration (FDA).
Upon developing countries adopting WHO guidelines for vaccine development and licensure, each country has its own responsibility to issue a national licensure, and to manage, deploy, and monitor the vaccine throughout its use in each nation. Building trust and acceptance of a licensed vaccine among the public is a task of communication by governments and healthcare personnel to ensure a vaccination campaign proceeds smoothly, saves lives, and enables economic recovery. When a vaccine is licensed, it will initially be in limited supply due to variable manufacturing, distribution, and logistical factors, requiring an allocation plan for the limited supply and which population segments should be prioritized to first receive the vaccine.
World Health Organization
Vaccines developed for multinational distribution via the United Nations Children's Fund (UNICEF) require pre-qualification by the WHO to ensure international standards of quality, safety, immunogenicity, and efficacy for adoption by numerous countries.
The process requires manufacturing consistency at WHO-contracted laboratories following Good Manufacturing Practice (GMP). When UN agencies are involved in vaccine licensure, individual nations collaborate by 1) issuing marketing authorization and a national license for the vaccine, its manufacturers, and distribution partners; and 2) conducting postmarketing surveillance, including records for adverse events after the vaccination program. The WHO works with national agencies to monitor inspections of manufacturing facilities and distributors for compliance with GMP and regulatory oversight.
Some countries choose to buy vaccines licensed by reputable national organizations, such as EMA, FDA, or national agencies in other affluent countries, but such purchases typically are more expensive and may not have distribution resources suitable to local conditions in developing countries.
In the European Union (EU), vaccines for pandemic pathogens, such as seasonal influenza, are licensed EU-wide where all the member states comply ("centralized"), are licensed for only some member states ("decentralized"), or are licensed on an individual national level. Generally, all EU states follow regulatory guidance and clinical programs defined by the European Committee for Medicinal Products for Human Use (CHMP), a scientific panel of the European Medicines Agency (EMA) responsible for vaccine licensure. The CHMP is supported by several expert groups who assess and monitor the progress of a vaccine before and after licensure and distribution.
Under the FDA, the process of establishing evidence for vaccine clinical safety and efficacy is the same as for the approval process for prescription drugs. If successful through the stages of clinical development, the vaccine licensing process is followed by a Biologics License Application which must provide a scientific review team (from diverse disciplines, such as physicians, statisticians, microbiologists, chemists) and comprehensive documentation for the vaccine candidate having efficacy and safety throughout its development. Also during this stage, the proposed manufacturing facility is examined by expert reviewers for GMP compliance, and the label must have a compliant description to enable health care providers' definition of vaccine-specific use, including its possible risks, to communicate and deliver the vaccine to the public. After licensure, monitoring of the vaccine and its production, including periodic inspections for GMP compliance, continue as long as the manufacturer retains its license, which may include additional submissions to the FDA of tests for potency, safety, and purity for each vaccine manufacturing step.
Drugs Controller General of India is the head of department of the Central Drugs Standard Control Organization of the Government of India responsible for approval of licences of specified categories of drugs such as vaccines AND others like blood and blood products, IV fluids, and sera in India.
Until a vaccine is in use for the general population, all potential adverse events from the vaccine may not be known, requiring manufacturers to conduct Phase IV studies for postmarketing surveillance of the vaccine while it is used widely in the public. The WHO works with UN member states to implement post-licensing surveillance. The FDA relies on a Vaccine Adverse Event Reporting System to monitor safety concerns about a vaccine throughout its use in the American public.
In order to provide the best protection, children are recommended to receive vaccinations as soon as their immune systems are sufficiently developed to respond to particular vaccines, with additional "booster" shots often required to achieve "full immunity". This has led to the development of complex vaccination schedules. Global recommendations of vaccination schedule are issued by Strategic Advisory Group of Experts and will be further translated by advisory committee at the country level with considering of local factors such as disease epidemiology, acceptability of vaccination, equity in local populations, and programmatic and financial constraint. In the United States, the Advisory Committee on Immunization Practices, which recommends schedule additions for the Centers for Disease Control and Prevention, recommends routine vaccination of children against hepatitis A, hepatitis B, polio, mumps, measles, rubella, diphtheria, pertussis, tetanus, HiB, chickenpox, rotavirus, influenza, meningococcal disease and pneumonia.
The large number of vaccines and boosters recommended (up to 24 injections by age two) has led to problems with achieving full compliance. To combat declining compliance rates, various notification systems have been instituted and many combination injections are now marketed (e.g., Pentavalent vaccine and MMRV vaccine), which protect against multiple diseases.
Besides recommendations for infant vaccinations and boosters, many specific vaccines are recommended for other ages or for repeated injections throughout life – most commonly for measles, tetanus, influenza, and pneumonia. Pregnant women are often screened for continued resistance to rubella. The human papillomavirus vaccine is recommended in the U.S. (as of 2011) and UK (as of 2009). Vaccine recommendations for the elderly concentrate on pneumonia and influenza, which are more deadly to that group. In 2006, a vaccine was introduced against shingles, a disease caused by the chickenpox virus, which usually affects the elderly.
Scheduling and dosing of a vaccination may be tailored to the level of immunocompetence of an individual and to optimize population-wide deployment of a vaccine when it supply is limited, e.g. in the setting of a pandemic.
Economics of development
One challenge in vaccine development is economic: Many of the diseases most demanding a vaccine, including HIV, malaria and tuberculosis, exist principally in poor countries. Pharmaceutical firms and biotechnology companies have little incentive to develop vaccines for these diseases because there is little revenue potential. Even in more affluent countries, financial returns are usually minimal and the financial and other risks are great.
Most vaccine development to date has relied on "push" funding by government, universities and non-profit organizations. Many vaccines have been highly cost effective and beneficial for public health. The number of vaccines actually administered has risen dramatically in recent decades. This increase, particularly in the number of different vaccines administered to children before entry into schools may be due to government mandates and support, rather than economic incentive.
According to the World Health Organization, the biggest barrier to vaccine production in less developed countries has not been patents, but the substantial financial, infrastructure, and workforce requirements needed for market entry. Vaccines are complex mixtures of biological compounds, and unlike the case for prescription drugs, there are no true generic vaccines. The vaccine produced by a new facility must undergo complete clinical testing for safety and efficacy by the manufacturer. For most vaccines, specific processes in technology are patented. These can be circumvented by alternative manufacturing methods, but this required R&D infrastructure and a suitably skilled workforce. In the case of a few relatively new vaccines, such as the human papillomavirus vaccine, the patents may impose an additional barrier.
When increased production of vaccines was urgently needed during the COVID-19 pandemic in 2021, the World Trade Organization and governments around the world evaluated whether to waive intellectual property rights and patents on COVID-19 vaccines, which would "eliminate all potential barriers to the timely access of affordable COVID-19 medical products, including vaccines and medicines, and scale up the manufacturing and supply of essential medical products."
Vaccine production is fundamentally different from other kinds of manufacturing – including regular pharmaceutical manufacturing – in that vaccines are intended to be administered to millions of people of whom the vast majority are perfectly healthy. This fact drives an extraordinarily rigorous production process with strict compliance requirements that go far beyond what is required of other products.
Depending upon the antigen, it can cost anywhere from US$50 to $500 million to build a vaccine production facility, which requires highly specialized equipment, clean rooms, and containment rooms. There is a global scarcity of personnel with the right combination of skills, expertise, knowledge, competence and personality to staff vaccine production lines. With the notable exceptions of Brazil, China, and India, many developing countries' educational systems are unable to provide enough qualified candidates, and vaccine makers based in such countries must hire expatriate personnel to keep production going.
Vaccine production has several stages. First, the antigen itself is generated. Viruses are grown either on primary cells such as chicken eggs (e.g., for influenza) or on continuous cell lines such as cultured human cells (e.g., for hepatitis A). Bacteria are grown in bioreactors (e.g., Haemophilus influenzae type b). Likewise, a recombinant protein derived from the viruses or bacteria can be generated in yeast, bacteria, or cell cultures.
After the antigen is generated, it is isolated from the cells used to generate it. A virus may need to be inactivated, possibly with no further purification required. Recombinant proteins need many operations involving ultrafiltration and column chromatography. Finally, the vaccine is formulated by adding adjuvant, stabilizers, and preservatives as needed. The adjuvant enhances the immune response to the antigen, stabilizers increase the storage life, and preservatives allow the use of multidose vials. Combination vaccines are harder to develop and produce, because of potential incompatibilities and interactions among the antigens and other ingredients involved.
The final stage in vaccine manufacture before distribution is fill and finish, which is the process of filling vials with vaccines and packaging them for distribution. Although this is a conceptually simple part of the vaccine manufacture process, it is often a bottleneck in the process of distributing and administering vaccines.
Vaccine production techniques are evolving. Cultured mammalian cells are expected to become increasingly important, compared to conventional options such as chicken eggs, due to greater productivity and low incidence of problems with contamination. Recombination technology that produces genetically detoxified vaccines is expected to grow in popularity for the production of bacterial vaccines that use toxoids. Combination vaccines are expected to reduce the quantities of antigens they contain, and thereby decrease undesirable interactions, by using pathogen-associated molecular patterns.
The companies with the highest market share in vaccine production are Merck, Sanofi, GlaxoSmithKline, Pfizer and Novartis, with 70% of vaccine sales concentrated in the EU or US (2013).: 42 Vaccine manufacturing plants require large capital investments ($50 million up to $300 million) and may take between 4 and 6 years to construct, with the full process of vaccine development taking between 10 and 15 years.: 43 Manufacturing in developing countries is playing an increasing role in supplying these countries, specifically with regards to older vaccines and in Brazil, India and China.: 47 The manufacturers in India are the most advanced in the developing world and include the Serum Institute of India, one of the largest producers of vaccines by number of doses and an innovator in processes, recently improving efficiency of producing the measles vaccine by 10 to 20-fold, due to switching to a MRC-5 cell culture instead of chicken eggs.: 48 China's manufacturing capabilities are focused on supplying their own domestic need, with Sinopharm (CNPGC) alone providing over 85% of the doses for 14 different vaccines in China.: 48 Brazil is approaching the point of supplying its own domestic needs using technology transferred from the developed world.: 49
One of the most common methods of delivering vaccines into the human body is injection.
The development of new delivery systems raises the hope of vaccines that are safer and more efficient to deliver and administer. Lines of research include liposomes and ISCOM (immune stimulating complex).
Notable developments in vaccine delivery technologies have included oral vaccines. Early attempts to apply oral vaccines showed varying degrees of promise, beginning early in the 20th century, at a time when the very possibility of an effective oral antibacterial vaccine was controversial. By the 1930s there was increasing interest in the prophylactic value of an oral typhoid fever vaccine for example.
An oral polio vaccine turned out to be effective when vaccinations were administered by volunteer staff without formal training; the results also demonstrated increased ease and efficiency of administering the vaccines. Effective oral vaccines have many advantages; for example, there is no risk of blood contamination. Vaccines intended for oral administration need not be liquid, and as solids, they commonly are more stable and less prone to damage or spoilage by freezing in transport and storage. Such stability reduces the need for a "cold chain": the resources required to keep vaccines within a restricted temperature range from the manufacturing stage to the point of administration, which, in turn, may decrease costs of vaccines.
A microneedle approach, which is still in stages of development, uses "pointed projections fabricated into arrays that can create vaccine delivery pathways through the skin".
An experimental needle-free vaccine delivery system is undergoing animal testing. A stamp-size patch similar to an adhesive bandage contains about 20,000 microscopic projections per square cm. This dermal administration potentially increases the effectiveness of vaccination, while requiring less vaccine than injection.
In veterinary medicine
Vaccinations of animals are used both to prevent their contracting diseases and to prevent transmission of disease to humans. Both animals kept as pets and animals raised as livestock are routinely vaccinated. In some instances, wild populations may be vaccinated. This is sometimes accomplished with vaccine-laced food spread in a disease-prone area and has been used to attempt to control rabies in raccoons.
Where rabies occurs, rabies vaccination of dogs may be required by law. Other canine vaccines include canine distemper, canine parvovirus, infectious canine hepatitis, adenovirus-2, leptospirosis, Bordetella, canine parainfluenza virus, and Lyme disease, among others.
Cases of veterinary vaccines used in humans have been documented, whether intentional or accidental, with some cases of resultant illness, most notably with brucellosis. However, the reporting of such cases is rare and very little has been studied about the safety and results of such practices. With the advent of aerosol vaccination in veterinary clinics, human exposure to pathogens not naturally carried in humans, such as Bordetella bronchiseptica, has likely increased in recent years. In some cases, most notably rabies, the parallel veterinary vaccine against a pathogen may be as much as orders of magnitude more economical than the human one.
DIVA (Differentiation of Infected from Vaccinated Animals), also known as SIVA (Segregation of Infected from Vaccinated Animals) vaccines, make it possible to differentiate between infected and vaccinated animals. DIVA vaccines carry at least one epitope less than the equivalent wild microorganism. An accompanying diagnostic test that detects the antibody against that epitope assists in identifying whether the animal has been vaccinated or not.
The first DIVA vaccines (formerly termed marker vaccines and since 1999 coined as DIVA vaccines) and companion diagnostic tests were developed by J. T. van Oirschot and colleagues at the Central Veterinary Institute in Lelystad, The Netherlands. They found that some existing vaccines against pseudorabies (also termed Aujeszky's disease) had deletions in their viral genome (among which was the gE gene). Monoclonal antibodies were produced against that deletion and selected to develop an ELISA that demonstrated antibodies against gE. In addition, novel genetically engineered gE-negative vaccines were constructed. Along the same lines, DIVA vaccines and companion diagnostic tests against bovine herpesvirus 1 infections have been developed.
The DIVA strategy has been applied in various countries to successfully eradicate pseudorabies virus from those countries. Swine populations were intensively vaccinated and monitored by the companion diagnostic test and, subsequently, the infected pigs were removed from the population. Bovine herpesvirus 1 DIVA vaccines are also widely used in practice. Considerable efforts are ongoing to apply the DIVA principle to a wide range of infectious diseases, such as classical swine fever, avian influenza, Actinobacillus pleuropneumonia and Salmonella infections in pigs.
Prior to the introduction of vaccination with material from cases of cowpox (heterotypic immunisation), smallpox could be prevented by deliberate variolation with smallpox virus. The earliest hints of the practice of variolation for smallpox in China come during the 10th century. The Chinese also practiced the oldest documented use of variolation, dating back to the fifteenth century. They implemented a method of "nasal insufflation" administered by blowing powdered smallpox material, usually scabs, up the nostrils. Various insufflation techniques have been recorded throughout the sixteenth and seventeenth centuries within China.: 60 Two reports on the Chinese practice of inoculation were received by the Royal Society in London in 1700; one by Martin Lister who received a report by an employee of the East India Company stationed in China and another by Clopton Havers.
Mary Wortley Montagu, who had witnessed variolation in Turkey, had her four-year-old daughter variolated in the presence of physicians of the Royal Court in 1721 upon her return to England. Later on that year, Charles Maitland conducted an experimental variolation of six prisoners in Newgate Prison in London. The experiment was a success, and soon variolation was drawing attention from the royal family, who helped promote the procedure. However, in 1783, several days after Prince Octavius of Great Britain was inoculated, he died. In 1796, the physician Edward Jenner took pus from the hand of a milkmaid with cowpox, scratched it into the arm of an 8-year-old boy, James Phipps, and six weeks later variolated the boy with smallpox, afterwards observing that he did not catch smallpox. Jenner extended his studies and, in 1798, reported that his vaccine was safe in children and adults, and could be transferred from arm-to-arm, which reduced reliance on uncertain supplies from infected cows. In 1804, the Spanish Balmis smallpox vaccination expedition to Spain's colonies Mexico and Philippines used the arm-to-arm transport method to get around the fact the vaccine survived for only 12 days in vitro. They used cowpox. Since vaccination with cowpox was much safer than smallpox inoculation, the latter, though still widely practiced in England, was banned in 1840.
Following on from Jenner's work, the second generation of vaccines was introduced in the 1880s by Louis Pasteur who developed vaccines for chicken cholera and anthrax, and from the late nineteenth century vaccines were considered a matter of national prestige. National vaccination policies were adopted and compulsory vaccination laws were passed. In 1931 Alice Miles Woodruff and Ernest Goodpasture documented that the fowlpox virus could be grown in embryonated chicken egg. Soon scientists began cultivating other viruses in eggs. Eggs were used for virus propagation in the development of a yellow fever vaccine in 1935 and an influenza vaccine in 1945. In 1959 growth media and cell culture replaced eggs as the standard method of virus propagation for vaccines.
Vaccinology flourished in the twentieth century, which saw the introduction of several successful vaccines, including those against diphtheria, measles, mumps, and rubella. Major achievements included the development of the polio vaccine in the 1950s and the eradication of smallpox during the 1960s and 1970s. Maurice Hilleman was the most prolific of the developers of the vaccines in the twentieth century. As vaccines became more common, many people began taking them for granted. However, vaccines remain elusive for many important diseases, including herpes simplex, malaria, gonorrhea, and HIV.
Generations of vaccines
First generation vaccines are whole-organism vaccines – either live and weakened, or killed forms. Live, attenuated vaccines, such as smallpox and polio vaccines, are able to induce killer T-cell (TC or CTL) responses, helper T-cell (TH) responses and antibody immunity. However, attenuated forms of a pathogen can convert to a dangerous form and may cause disease in immunocompromised vaccine recipients (such as those with AIDS). While killed vaccines do not have this risk, they cannot generate specific killer T cell responses and may not work at all for some diseases.
Second generation vaccines were developed to reduce the risks from live vaccines. These are subunit vaccines, consisting of specific protein antigens (such as tetanus or diphtheria toxoid) or recombinant protein components (such as the hepatitis B surface antigen). They can generate TH and antibody responses, but not killer T cell responses.
RNA vaccines and DNA vaccines are examples of third generation vaccines. In 2016 a DNA vaccine for the Zika virus began testing at the National Institutes of Health. Separately, Inovio Pharmaceuticals and GeneOne Life Science began tests of a different DNA vaccine against Zika in Miami. Manufacturing the vaccines in volume was unsolved as of 2016. Clinical trials for DNA vaccines to prevent HIV are underway. mRNA vaccines such as BNT162b2 were developed in the year 2020 with the help of Operation Warp Speed and massively deployed to combat the COVID-19 pandemic. In 2021, Katalin Karikó and Drew Weissman received Columbia University's Horwitz Prize for their pioneering research in mRNA vaccine technology.
This section needs to be updated.(June 2018)
Since at least 2013, scientists were trying to develop synthetic 3rd-generation vaccines by reconstructing the outside structure of a virus; it was hoped that this will help prevent vaccine resistance.
Principles that govern the immune response can now be used in tailor-made vaccines against many noninfectious human diseases, such as cancers and autoimmune disorders. For example, the experimental vaccine CYT006-AngQb has been investigated as a possible treatment for high blood pressure. Factors that affect the trends of vaccine development include progress in translatory medicine, demographics, regulatory science, political, cultural, and social responses.
Plants as bioreactors for vaccine production
The idea of vaccine production via transgenic plants was identified as early as 2003. Plants such as tobacco, potato, tomato, and banana can have genes inserted that cause them to produce vaccines usable for humans. In 2005, bananas were developed that produce a human vaccine against hepatitis B. Another example is the expression of a fusion protein in alfalfa transgenic plants for the selective directioning to antigen presenting cells, therefore increasing vaccine potency against Bovine Viral Diarrhea Virus (BVDV).
- Biologics Control Act
- Coalition for Epidemic Preparedness Innovations
- Flying syringe
- Immunization registry
- List of vaccine ingredients
- List of vaccine topics
- Non-specific effect of vaccines
- OPV AIDS hypothesis
- Preventive healthcare
- Reverse vaccinology
- Timeline of vaccines
- Vaccine adverse event (safety issues)
- Vaccine cooler
- Vaccine failure
- Vaccine hesitancy
- Viral vector
- Virus-like particle
- Nasal vaccine
- "Expanded Practice Standards" (PDF). Iowa Administrative Code. 2019.
- Melief CJ, van Hall T, Arens R, Ossendorp F, van der Burg SH (September 2015). "Therapeutic cancer vaccines". The Journal of Clinical Investigation. 125 (9): 3401–3412. doi:10.1172/JCI80009. PMC 4588240. PMID 26214521.
- Bol KF, Aarntzen EH, Pots JM, Olde Nordkamp MA, van de Rakt MW, Scharenborg NM, de Boer AJ, van Oorschot TG, Croockewit SA, Blokx WA, Oyen WJ, Boerman OC, Mus RD, van Rossum MM, van der Graaf CA, Punt CJ, Adema GJ, Figdor CG, de Vries IJ, Schreibelt G (March 2016). "Prophylactic vaccines are potent activators of monocyte-derived dendritic cells and drive effective anti-tumor responses in melanoma patients at the cost of toxicity". Cancer Immunology, Immunotherapy. 65 (3): 327–339. doi:10.1007/s00262-016-1796-7. PMC 4779136. PMID 26861670.
- Brotherton J (2015). "HPV prophylactic vaccines: lessons learned from 10 years experience". Future Virology. 10 (8): 999–1009. doi:10.2217/fvl.15.60.
- Frazer IH (May 2014). "Development and implementation of papillomavirus prophylactic vaccines". Journal of Immunology. 192 (9): 4007–4011. doi:10.4049/jimmunol.1490012. PMID 24748633.
- Ledford, Heidi (2020-08-17). "What the immune response to the coronavirus says about the prospects for a vaccine". Nature. 585 (7823): 20–21. doi:10.1038/d41586-020-02400-7. PMID 32811981. S2CID 221180503.
- *United States Centers for Disease Control and Prevention (2011). A CDC framework for preventing infectious diseases. Archived 2017-08-29 at the Wayback Machine Accessed 11 September 2012. "Vaccines are our most effective and cost-saving tools for disease prevention, preventing untold suffering and saving tens of thousands of lives and billions of dollars in healthcare costs each year."
- American Medical Association (2000). Vaccines and infectious diseases: putting risk into perspective. Archived 2015-02-05 at the Wayback Machine Accessed 11 September 2012. "Vaccines are the most effective public health tool ever created."
- Public Health Agency of Canada. Vaccine-preventable diseases. Archived 2015-03-13 at the Wayback Machine Accessed 11 September 2012. "Vaccines still provide the most effective, longest-lasting method of preventing infectious diseases in all age groups."
- United States National Institute of Allergy and Infectious Diseases (NIAID). NIAID Biodefense Research Agenda for Category B and C Priority Pathogens. Archived 2016-03-04 at the Wayback Machine Accessed 11 September 2012. "Vaccines are the most effective method of protecting the public against infectious diseases."
- Zimmer, Carl (20 November 2020). "2 Companies Say Their Vaccines Are 95% Effective. What Does That Mean? You might assume that 95 out of every 100 people vaccinated will be protected from Covid-19. But that's not how the math works". The New York Times. Retrieved 21 November 2020.
- Fiore AE, Bridges CB, Cox NJ (2009). "Seasonal influenza vaccines". Vaccines for Pandemic Influenza. Curr. Top. Microbiol. Immunol. Current Topics in Microbiology and Immunology. 333. pp. 43–82. doi:10.1007/978-3-540-92165-3_3. ISBN 978-3-540-92164-6. PMID 19768400.
- Chang Y, Brewer NT, Rinas AC, Schmitt K, Smith JS (July 2009). "Evaluating the impact of human papillomavirus vaccines". Vaccine. 27 (32): 4355–4362. doi:10.1016/j.vaccine.2009.03.008. PMID 19515467.
- Liesegang TJ (August 2009). "Varicella zoster virus vaccines: effective, but concerns linger". Canadian Journal of Ophthalmology. 44 (4): 379–384. doi:10.3129/i09-126. PMID 19606157. S2CID 662998.
- World Health Organization, Global Vaccine Action Plan 2011-2020. Archived 2014-04-14 at the Wayback Machine Geneva, 2012.
- Baxby D (January 1999). "Edward Jenner's Inquiry; a bicentenary analysis". Vaccine. 17 (4): 301–307. doi:10.1016/s0264-410x(98)00207-2. PMID 9987167.
- Pasteur L (1881). "Address on the Germ Theory". Lancet. 118 (3024): 271–272. doi:10.1016/s0140-6736(02)35739-8.
- "Measles Vaccination CDC". 2018-02-05.
- Orenstein WA, Bernier RH, Dondero TJ, Hinman AR, Marks JS, Bart KJ, Sirotkin B (1985). "Field evaluation of vaccine efficacy". Bulletin of the World Health Organization. 63 (6): 1055–1068. PMC 2536484. PMID 3879673.
- Jan 11, Hub staff report / Published; 2017 (2017-01-11). "The science is clear: Vaccines are safe, effective, and do not cause autism". The Hub. Retrieved 2019-04-16.CS1 maint: numeric names: authors list (link)
- Ellenberg SS, Chen RT (1997). "The complicated task of monitoring vaccine safety". Public Health Reports. 112 (1): 10–20, discussion 21. PMC 1381831. PMID 9018282.
- "Vaccine Safety: The Facts". HealthyChildren.org. Retrieved 2019-04-16.
- Grammatikos AP, Mantadakis E, Falagas ME (June 2009). "Meta-analyses on pediatric infections and vaccines". Infectious Disease Clinics of North America. 23 (2): 431–457. doi:10.1016/j.idc.2009.01.008. PMID 19393917.
- Wiedermann, Ursula; Garner-Spitzer, Erika; Wagner, Angelika (January 2016). "Primary vaccine failure to routine vaccines: Why and what to do?". Human Vaccines & Immunotherapeutics. 12 (1): 239–243. doi:10.1080/21645515.2015.1093263. PMC 4962729. PMID 26836329.
- Neighmond P (2010-02-07). "Adapting Vaccines For Our Aging Immune Systems". Morning Edition. NPR. Archived from the original on 2013-12-16. Retrieved 2014-01-09.
- Schlegel M, Osterwalder JJ, Galeazzi RL, Vernazza PL (August 1999). "Comparative efficacy of three mumps vaccines during disease outbreak in Eastern Switzerland: cohort study". BMJ. 319 (7206): 352. doi:10.1136/bmj.319.7206.352. PMC 32261. PMID 10435956.
- Préziosi MP, Halloran ME (September 2003). "Effects of pertussis vaccination on disease: vaccine efficacy in reducing clinical severity". Clinical Infectious Diseases. 37 (6): 772–779. doi:10.1086/377270. PMID 12955637.
- Miller, E.; Beverley, P. C. L.; Salisbury, D. M. (2002-07-01). "Vaccine programmes and policies". British Medical Bulletin. 62 (1): 201–211. doi:10.1093/bmb/62.1.201. ISSN 0007-1420. PMID 12176861.
- Orenstein WA, Papania MJ, Wharton ME (May 2004). "Measles elimination in the United States". The Journal of Infectious Diseases. 189 Suppl 1 (Suppl 1): S1-3. doi:10.1086/377693. PMID 15106120.
- "Measles – United States, January 1 – April 25, 2008". MMWR. Morbidity and Mortality Weekly Report. 57 (18): 494–498. May 2008. PMID 18463608. Archived from the original on October 11, 2017.
- "WHO | Smallpox". WHO. World Health Organization. Retrieved 2019-04-16.
- "WHO South-East Asia Region certified polio-free". WHO. 27 March 2014. Archived from the original on 27 March 2014. Retrieved November 3, 2014.
- "19 July 2017 Vaccines promoted as key to stamping out drug-resistant microbes "Immunization can stop resistant infections before they get started, say scientists from industry and academia."". Archived from the original on July 22, 2017.
- Sullivan P (2005-04-13). "Maurice R. Hilleman dies; created vaccines". Wash. Post. Archived from the original on 2012-10-20. Retrieved 2014-01-09.
- Dudley, Matthew Z; Halsey, Neal A; Omer, Saad B; Orenstein, Walter A; O'Leary, Sean T; Limaye, Rupali J; Salmon, Daniel A (May 2020). "The state of vaccine safety science: systematic reviews of the evidence". The Lancet Infectious Diseases. 20 (5): e80–e89. doi:10.1016/s1473-3099(20)30130-4. ISSN 1473-3099. PMID 32278359. S2CID 215751248.
- Maglione MA, Das L, Raaen L, Smith A, Chari R, Newberry S, Shanman R, Perry T, Goetz MB, Gidengil C (August 2014). "Safety of vaccines used for routine immunization of U.S. children: a systematic review". Pediatrics. 134 (2): 325–337. doi:10.1542/peds.2014-1079. PMID 25086160.
- "Possible Side-effects from Vaccines". Centers for Disease Control and Prevention. 2018-07-12. Archived from the original on 17 March 2017. Retrieved 24 February 2014.
- "Seasonal Flu Shot – Seasonal Influenza (Flu)". CDC. 2018-10-02. Archived from the original on 2015-10-01. Retrieved 2017-09-17.
- Wiedermann U, Garner-Spitzer E, Wagner A (2016). "Primary vaccine failure to routine vaccines: Why and what to do?". Human Vaccines and Immunotherapeutics. 12 (1): 239–243. doi:10.1080/21645515.2015.1093263. ISSN 2164-554X. PMC 4962729. PMID 26836329.
- Looker C, Heath K (2011). "No-fault compensation following adverse events attributed to vaccination: a review of international programmes". Bulletin of the World Health Organization. Word Health Organisation. 89 (5): 371–378. doi:10.2471/BLT.10.081901. PMC 3089384. PMID 21556305.
- "Vaccine Types". National Institute of Allergy and Infectious Diseases. 2012-04-03. Archived from the original on 2015-09-05. Retrieved 2015-01-27.
- Sinha JK, Bhattacharya S. A Text Book of Immunology (Google Books Preview). Academic Publishers. p. 318. ISBN 978-81-89781-09-5. Retrieved 2014-01-09.
- "Types of Vaccines". Archived from the original on 2017-07-29. Retrieved October 19, 2017.
- Batah, Aly; Ahmad, Tarek (2020-06-15). "The development of ghost vaccines trials". Expert Review of Vaccines. 19 (6): 549–562. doi:10.1080/14760584.2020.1777862. ISSN 1476-0584. PMID 32500816. S2CID 219331100.
- "Different Types of Vaccines | History of Vaccines". www.historyofvaccines.org. Retrieved 2019-06-14.
- "Different Types of Vaccines | History of Vaccines". www.historyofvaccines.org. Retrieved 2019-05-03.
- "Types of Vaccines". coastalcarolinaresearch.com. Retrieved 2019-05-03.
- Philadelphia, The Children's Hospital of (2014-08-18). "A Look at Each Vaccine: Hepatitis B Vaccine". www.chop.edu. Retrieved 2019-06-14.
- "HPV Vaccine | Human Papillomavirus | CDC". www.cdc.gov. 2019-05-13. Retrieved 2019-06-14.
- Williamson, E. D.; Eley, S. M.; Griffin, K. F.; Green, M.; Russell, P.; Leary, S. E.; Oyston, P. C.; Easterbrook, T.; Reddin, K. M. (December 1995). "A new improved sub-unit vaccine for plague: the basis of protection". FEMS Immunology and Medical Microbiology. 12 (3–4): 223–230. doi:10.1111/j.1574-695X.1995.tb00196.x. ISSN 0928-8244. PMID 8745007.
- "Polysaccharide Protein Conjugate Vaccines". www.globalhealthprimer.emory.edu. Retrieved 2019-06-14.
- Pollard AJ, Bijker EM (2020-12-22). "A guide to vaccinology: from basic principles to new developments". Nature Reviews Immunology. 21 (2): 83–100. doi:10.1038/s41577-020-00479-7. ISSN 1474-1741. PMC 7754704. PMID 33353987.
- Pol L, Stork M, Ley P (2015-11-11). "Outer membrane vesicles as platform vaccine technology". Biotechnology Journal. 10 (11): 1689–1706. doi:10.1002/biot.201400395. ISSN 1860-7314. PMC 4768646. PMID 26912077.
- Scott (April 2004). "Classifying Vaccines" (PDF). BioProcesses International: 14–23. Archived (PDF) from the original on 2013-12-12. Retrieved 2014-01-09.
- "Vaccine Types". Vaccines.org. Office of Infectious Disease of the United States Department of Health and Human Services. Retrieved 13 March 2021.
- "Understanding and Explaining Viral Vector COVID-19 Vaccines". Centers for Disease Control and Prevention. Retrieved 13 March 2021.
- Garde, Damian; Feuerstein, Adam (1 November 2020). "How nanotechnology helps mRNA Covid-19 vaccines work". STAT. Retrieved 21 December 2020.
- CDC (11 February 2020). "COVID-19 and Your Health". Centers for Disease Control and Prevention. Retrieved 21 December 2020.
- Banks, Marcus A. (16 July 2020). "What Are mRNA Vaccines, and Could They Work Against COVID-19?". Smithsonian Magazine. Retrieved 21 December 2020.
- Branswell, Helen (19 December 2020). "FDA grants authorization to Moderna's Covid-19 vaccine". STAT. Retrieved 21 December 2020.
- Kim W, Liau LM (January 2010). "Dendritic cell vaccines for brain tumors". Neurosurgery Clinics of North America. 21 (1): 139–157. doi:10.1016/j.nec.2009.09.005. PMC 2810429. PMID 19944973.
- Anguille S, Smits EL, Lion E, van Tendeloo VF, Berneman ZN (June 2014). "Clinical use of dendritic cells for cancer therapy". The Lancet. Oncology. 15 (7): e257–267. doi:10.1016/S1470-2045(13)70585-0. PMID 24872109.
- McKenzie, David (26 May 2018). "Fear and failure: How Ebola sparked a global health revolution". CNN. Retrieved 26 May 2018.
- Meri S, Jördens M, Jarva H (December 2008). "Microbial complement inhibitors as vaccines". Vaccine. 26 Suppl 8: I113–117. doi:10.1016/j.vaccine.2008.11.058. PMID 19388175.
- Lowe (2008). "Plasmid DNA as Prophylactic and Therapeutic vaccines for Cancer and Infectious Diseases". Plasmids: Current Research and Future Trends. Caister Academic Press. ISBN 978-1-904455-35-6.
- "Monovalent" at Dorland's Medical Dictionary
- Polyvalent vaccine at Dorlands Medical Dictionary Archived March 7, 2012, at the Wayback Machine
- "Questions And Answers On Monovalent Oral Polio Vaccine Type 1 (mOPV1)'Issued Jointly By WHO and UNICEF'". Pediatric Oncall. 2 (8). 3. What advantages does mOPV1 have over trivalent oral polio vaccine (tOPV)?. 2005-01-08. Archived from the original on 2012-02-29.
- Sutter RW, Cochi SL, Melnick JL (1999). "Live attenuated polio vaccines". In Plotkin SA, Orenstein WA (eds.). Vaccines. Philadelphia: W. B. Saunders. pp. 364–408.
- Kanesa-thasan N, Sun W, Kim-Ahn G, Van Albert S, Putnak JR, King A, Raengsakulsrach B, Christ-Schmidt H, Gilson K, Zahradnik JM, Vaughn DW, Innis BL, Saluzzo JF, Hoke CH (April 2001). "Safety and immunogenicity of attenuated dengue virus vaccines (Aventis Pasteur) in human volunteers". Vaccine. 19 (23–24): 3179–3188. CiteSeerX 10.1.1.559.8311. doi:10.1016/S0264-410X(01)00020-2. PMID 11312014.
- Engler, Renata J. M.; Greenwood, John T.; Pittman, Phillip R.; Grabenstein, John D. (2006-08-01). "Immunization to Protect the US Armed Forces: Heritage, Current Practice, and Prospects". Epidemiologic Reviews. 28 (1): 3–26. doi:10.1093/epirev/mxj003. ISSN 0193-936X. PMID 16763072.
- Sox, Harold C.; Liverman, Catharyn T.; Fulco, Carolyn E.; War, Institute of Medicine (US) Committee on Health Effects Associated with Exposures During the Gulf (2000). Vaccines. National Academies Press (US).
- "Institute for Vaccine Safety – Thimerosal Table". Archived from the original on 2005-12-10.
- Wharton, Melinda E.; National Vaccine Advisory committee "U.S.A. national vaccine plan" Archived 2016-05-04 at the Wayback Machine
- "Measurements of Non-gaseous air pollutants > Metals". npl.co.uk. National Physics Laboratory. Archived from the original on 29 September 2007. Retrieved 28 June 2020.
- "Thimerosal in vaccines". Center for Biologics Evaluation and Research, U.S. Food and Drug Administration. 2007-09-06. Archived from the original on 2013-01-06. Retrieved 2007-10-01.
- Bigham M, Copes R (2005). "Thiomersal in vaccines: balancing the risk of adverse effects with the risk of vaccine-preventable disease". Drug Safety. 28 (2): 89–101. doi:10.2165/00002018-200528020-00001. PMID 15691220. S2CID 11570020.
- Offit PA (September 2007). "Thimerosal and vaccines – a cautionary tale". The New England Journal of Medicine. 357 (13): 1278–1279. doi:10.1056/NEJMp078187. PMID 17898096. S2CID 36318722.
- March 5, Reuters Updated; 2019 (2019-03-05). "Another study, this one of 657k kids, finds MMR vaccine doesn't cause autism | Montreal Gazette". Retrieved 2019-03-13.CS1 maint: numeric names: authors list (link)
- Hoffman J (2019-03-05). "One More Time, With Big Data: Measles Vaccine Doesn't Cause Autism". The New York Times. ISSN 0362-4331. Retrieved 2019-03-13.
- CDC (2018-07-12). "Ingredients of Vaccines – Fact Sheet". Archived from the original on December 17, 2009. Retrieved December 20, 2009.
- The mercury levels in the table, unless otherwise indicated, are taken from Mercury Levels in Commercial Fish and Shellfish (1990-2010) Archived 2015-05-03 at the Wayback Machine U.S. Food and Drug Administration. Accessed 8 January 2012.
- Centers for Disease Control and Prevention (12 November 2020), U.S. Vaccine Names, retrieved 2021-08-21.
- Centers for Disease Control and Prevention (2018-08-07), Tetanus (Lockjaw) Vaccination, archived from the original on 2016-05-16, retrieved 2016-05-21.
- Centers for Disease Control and Prevention (2018-02-02), Vaccine Acronyms and Abbreviations [Abbreviations used on U.S. immunization records], archived from the original on 2017-06-02, retrieved 2017-05-22.
- "Principles and considerations for adding a vaccine to a national immunization programme" (PDF). World Health Organization. 1 April 2014. Archived (PDF) from the original on 29 September 2020. Retrieved 17 August 2020.
- Bok, Karin; Sitar, Sandra; Graham, Barney S.; Mascola, John R. (August 2021). "Accelerated COVID-19 vaccine development: milestones, lessons, and prospects". Immunity. 54 (8): 1636–1651. doi:10.1016/j.immuni.2021.07.017. PMC 8328682. PMID 34348117.
- Wijnans, Leonoor; Voordouw, Bettie (11 December 2015). "A review of the changes to the licensing of influenza vaccines in Europe". Influenza and Other Respiratory Viruses. 10 (1): 2–8. doi:10.1111/irv.12351. ISSN 1750-2640. PMC 4687503. PMID 26439108.
- Offit, Paul A. (2020). "Making vaccines: Licensure, recommendations and requirements". Children's Hospital of Philadelphia. Archived from the original on 8 September 2020. Retrieved 20 August 2020.
- Toner E, Barnill A, Krubiner C, Bernstein J, Privor-Dumm L, Watson M, et al. (2020). Interim Framework for COVID-19 Vaccine Allocation and Distribution in the United States (PDF) (Report). Baltimore, MD: Johns Hopkins Center for Health Security. Archived (PDF) from the original on 22 August 2020. Retrieved 24 August 2020.
- Dooling K, Marin M, Wallace M, McClung N, Chamberland M, Lee GM, et al. (December 2020). "The Advisory Committee on Immunization Practices' Updated Interim Recommendation for Allocation of COVID-19 Vaccine – United States, December 2020". MMWR. Morbidity and Mortality Weekly Report. 69 (5152): 1657–1660. doi:10.15585/mmwr.mm695152e2. PMID 33382671.
- "Vaccine product approval process". U.S. Food and Drug Administration (FDA). 30 January 2020. Archived from the original on 27 September 2020. Retrieved 17 August 2020.
- Steffen, Christoph A.; Henaff, Louise; et al. (8 April 2021). "Evidence-informed vaccination decision-making in countries: Progress, challenges and opportunities". Vaccine. Elsevier. 39 (15): 2146–2152. doi:10.1016/j.vaccine.2021.02.055. PMID 33712350.
- "ACIP Vaccine Recommendations Home Page". CDC. 2013-11-15. Archived from the original on 2013-12-31. Retrieved 2014-01-10.
- "Vaccine Status Table". Red Book Online. American Academy of Pediatrics. April 26, 2011. Archived from the original on December 27, 2013. Retrieved January 9, 2013.
- "HPV Vaccine Safety". Centers for Disease Control and Prevention (CDC). 2013-12-20. Archived from the original on 2009-11-10. Retrieved 2014-01-10.
- "HPV vaccine in the clear". NHS choices. 2009-10-02. Archived from the original on 2014-01-10. Retrieved 2014-01-10.
- "Zostavax EPAR". European Medicines Agency (EMA). 29 July 2021. Retrieved 1 September 2021.
- Dooling, Kathleen (2021-08-13). "The Advisory Committee on Immunization Practices' Updated Interim Recommendation for Allocation of COVID-19 Vaccine – United States, December 2020" (PDF). CDC the Advisory Committee on Immunization Practices. 69 (5152): 1657–1660. PMID 33382671.
- Hunziker, Patrick (2021-07-24). "Personalized-dose Covid-19 vaccination in a wave of virus Variants of Concern: Trading individual efficacy for societal benefit". Precision Nanomedicine. 4 (3): 805–820. doi:10.33218/001c.26101. ISSN 2639-9431.
- Goodman JL (2005-05-04). "Statement by Jesse L. Goodman, M.D., M.P.H. Director Center for Biologics, Evaluation and Research Food and Drug Administration U.S. Department of Health and Human Services on US Influenza Vaccine Supply and Preparations for the Upcoming Influenza Season before Subcommittee on Oversight and Investigations Committee on Energy and Commerce United States House of Representatives". Archived from the original on 2008-09-21. Retrieved 2008-06-15.
- Olesen OF, Lonnroth A, Mulligan B (January 2009). "Human vaccine research in the European Union". Vaccine. 27 (5): 640–645. doi:10.1016/j.vaccine.2008.11.064. PMC 7115654. PMID 19059446.
- Jit M, Newall AT, Beutels P (April 2013). "Key issues for estimating the impact and cost-effectiveness of seasonal influenza vaccination strategies". Human Vaccines & Immunotherapeutics. 9 (4): 834–840. doi:10.4161/hv.23637. PMC 3903903. PMID 23357859.
- Newall AT, Reyes JF, Wood JG, McIntyre P, Menzies R, Beutels P (February 2014). "Economic evaluations of implemented vaccination programmes: key methodological challenges in retrospective analyses". Vaccine. 32 (7): 759–765. doi:10.1016/j.vaccine.2013.11.067. PMID 24295806.
- Roser, Max; Vanderslott, Samantha (2013-05-10). "Vaccination". Our World in Data.
- "Increasing Access to Vaccines Through Technology Transfer and Local Production" (PDF). World Health Organization. 2011. Archived (PDF) from the original on 2015-11-23.
- Christy Somos (7 May 2021). "Everything you need to know about the WTO's COVID-19 vaccine patent proposal". CTV News. Retrieved 23 May 2021.
- Gomez, Phillip L.; Robinson, James M.; Rogalewicz, James (2008). "Chapter 4: Vaccine Manufacturing". In Plotkin, Stanley A.; Orenstein, Walter A.; Offit, Paul A. (eds.). Vaccines (5th ed.). New York: Saunders Elsevier. pp. 45–58. ISBN 9781437721584. Retrieved March 26, 2021.
- Plotkin, Stanley; Robinson, James M.; Cunningham, Gerard; Iqbal, Robyn; Larsen, Shannon (24 July 2017). "The complexity and cost of vaccine manufacturing – An overview". Vaccine. 35 (33): 4064–4071. doi:10.1016/j.vaccine.2017.06.003. PMC 5518734. PMID 28647170.
- "Three ways to make a vaccine" (infographic). Archived from the original on 2015-12-23. Retrieved 2015-08-05, in Stein, Rob (24 November 2009). "Vaccine system remains antiquated". The Washington Post. Archived from the original on 19 October 2017.
- Muzumdar JM, Cline RR (2009). "Vaccine supply, demand, and policy: a primer". Journal of the American Pharmacists Association. 49 (4): e87–99. doi:10.1331/JAPhA.2009.09007. PMC 7185851. PMID 19589753.
- "Components of a vaccine". Archived from the original on 2017-06-13.
- Bae K, Choi J, Jang Y, Ahn S, Hur B (April 2009). "Innovative vaccine production technologies: the evolution and value of vaccine production technologies". Archives of Pharmacal Research. 32 (4): 465–480. doi:10.1007/s12272-009-1400-1. PMID 19407962. S2CID 9066150.
- "Vaccine Taskforce Aims" (PDF). assets.publishing.service.gov.uk. 6 April 2020. Retrieved 2020-07-26.
- Pagliusi, Sonia; Jarrett, Stephen; Hayman, Benoit; Kreysa, Ulrike; Prasad, Sai D.; Reers, Martin; Hong Thai, Pham; Wu, Ke; Zhang, Youn Tao; Baek, Yeong Ok; Kumar, Anand (July 2020). "Emerging manufacturers engagements in the COVID −19 vaccine research, development and supply". Vaccine. 38 (34): 5418–5423. doi:10.1016/j.vaccine.2020.06.022. PMC 7287474. PMID 32600908.
- Miller, Joe; Kuchler, Hannah (2020-04-28). "Drugmakers race to scale up vaccine capacity". www.ft.com. Retrieved 2020-07-26.
- Plotkin, Stanley A.; Orenstein, Walter A.; Offit, Paul A.; Edwards, Kathryn M. (2017). Vaccines. Elsevier. ISBN 9780323393010.
- Morein B, Hu KF, Abusugra I (June 2004). "Current status and potential application of ISCOMs in veterinary medicine". Advanced Drug Delivery Reviews. 56 (10): 1367–1382. doi:10.1016/j.addr.2004.02.004. PMID 15191787.
- American Medicine. American-Medicine Publishing Company. 1926.
- South African Institute for Medical Research (1929). Annual report [Jaarverslag]. South African Institute for Medical Research – Suid-Afrikaanse Instituut vir Mediese Navorsing.
- Khan FA (2011-09-20). Biotechnology Fundamentals. CRC Press. p. 270. ISBN 978-1-4398-2009-4.
- Giudice EL, Campbell JD (April 2006). "Needle-free vaccine delivery". Advanced Drug Delivery Reviews. 58 (1): 68–89. doi:10.1016/j.addr.2005.12.003. PMID 16564111.
- WHO to trial Nanopatch needle-free delivery system| ABC News, 16 Sep 2014| "Needle-free polio vaccine a 'game-changer'". 2014-09-16. Archived from the original on 2015-04-02. Retrieved 2015-09-15.
- "Australian scientists develop 'needle-free' vaccination". The Sydney Morning Herald. 18 August 2013. Archived from the original on 25 September 2015.
- "Vaxxas raises $25m to take Brisbane's Nanopatch global". Business Review Weekly. 2015-02-10. Archived from the original on 2015-03-16. Retrieved 2015-03-05.
- "Australian scientists develop 'needle-free' vaccination". The Hindu. Chennai, India. 28 September 2011. Archived from the original on 1 January 2014.
- "Needle-free nanopatch vaccine delivery system". News Medical. 3 August 2011. Archived from the original on 11 May 2012.
- Patel JR, Heldens JG (March 2009). "Immunoprophylaxis against important virus disease of horses, farm animals and birds". Vaccine. 27 (12): 1797–1810. doi:10.1016/j.vaccine.2008.12.063. PMC 7130586. PMID 19402200.
- Berkelman RL (August 2003). "Human illness associated with use of veterinary vaccines". Clinical Infectious Diseases. 37 (3): 407–414. doi:10.1086/375595. PMID 12884166.
- van Oirschot JT, Rziha HJ, Moonen PJ, Pol JM, van Zaane D (June 1986). "Differentiation of serum antibodies from pigs vaccinated or infected with Aujeszky's disease virus by a competitive enzyme immunoassay". The Journal of General Virology. 67 (Pt 6) (6): 1179–1182. doi:10.1099/0022-1317-67-6-1179. PMID 3011974.
- van Oirschot JT (August 1999). "Diva vaccines that reduce virus transmission". Journal of Biotechnology. 73 (2–3): 195–205. doi:10.1016/S0168-1656(99)00121-2. PMID 10486928.
- van Oirschot JT, Gielkens AL, Moormann RJ, Berns AJ (June 1990). "Marker vaccines, virus protein-specific antibody assays and the control of Aujeszky's disease". Veterinary Microbiology. 23 (1–4): 85–101. doi:10.1016/0378-1135(90)90139-M. PMID 2169682.
- Kaashoek MJ, Moerman A, Madić J, Rijsewijk FA, Quak J, Gielkens AL, van Oirschot JT (April 1994). "A conventionally attenuated glycoprotein E-negative strain of bovine herpesvirus type 1 is an efficacious and safe vaccine". Vaccine. 12 (5): 439–444. doi:10.1016/0264-410X(94)90122-8. PMID 8023552.
- Hulst MM, Westra DF, Wensvoort G, Moormann RJ (September 1993). "Glycoprotein E1 of hog cholera virus expressed in insect cells protects swine from hog cholera". Journal of Virology. 67 (9): 5435–5442. doi:10.1128/JVI.67.9.5435-5442.1993. PMC 237945. PMID 8350404.
- Capua I, Terregino C, Cattoli G, Mutinelli F, Rodriguez JF (February 2003). "Development of a DIVA (Differentiating Infected from Vaccinated Animals) strategy using a vaccine containing a heterologous neuraminidase for the control of avian influenza". Avian Pathology. 32 (1): 47–55. doi:10.1080/0307945021000070714. PMID 12745380. S2CID 22827454.
- Maas A, Meens J, Baltes N, Hennig-Pauka I, Gerlach GF (November 2006). "Development of a DIVA subunit vaccine against Actinobacillus pleuropneumoniae infection". Vaccine. 24 (49–50): 7226–7237. doi:10.1016/j.vaccine.2006.06.047. PMID 17027123.
- Leyman B, Boyen F, Van Parys A, Verbrugghe E, Haesebrouck F, Pasmans F (May 2011). "Salmonella Typhimurium LPS mutations for use in vaccines allowing differentiation of infected and vaccinated pigs". Vaccine. 29 (20): 3679–3685. doi:10.1016/j.vaccine.2011.03.004. hdl:1854/LU-1201519. PMID 21419163. Archived from the original on 2017-10-28.
- Needham, Joseph (2000). Science and Civilisation in China: Volume 6, Biology and Biological Technology, Part 6, Medicine. Cambridge University Press. p. 154. ISBN 9780521632621.
- Williams G (2010). Angel of Death. Basingstoke: Palgrave Macmillan. ISBN 978-0-230-27471-6.
- Silverstein, Arthur M. (2009). A History of Immunology (2nd ed.). Academic Press. p. 293. ISBN 9780080919461.
- Fenner, F.; Henderson, D.A.; Arita, I.; Jezek, Z.; Ladnyi, I.D. (1988). Smallpox and its Eradication. Geneva: World Health Organization. ISBN 92-4-156110-6.
- Baxby, Derrick (1984). "A Death from Inoculated Smallpox in the English Royal Family". Med Hist. 28 (3): 303–307. doi:10.1017/s0025727300035961. PMC 1139449. PMID 6390027.
- Stern AM, Markel H (2005). "The history of vaccines and immunization: familiar patterns, unew challenges". Health Affairs. 24 (3): 611–621. doi:10.1377/hlthaff.24.3.611. PMID 15886151.
- Dunn PM (January 1996). "Dr Edward Jenner (1749-1823) of Berkeley, and vaccination against smallpox" (PDF). Archives of Disease in Childhood: Fetal and Neonatal Edition. 74 (1): F77–78. doi:10.1136/fn.74.1.F77. PMC 2528332. PMID 8653442. Archived from the original (PDF) on 2011-07-08.
- Exhibition tells story of Spanish children used as vaccine fridges in 1803 The Guardian, 2021
- Van Sant JE (2008). "The Vaccinators: Smallpox, Medical Knowledge, and the 'Opening' of Japan". J Hist Med Allied Sci. 63 (2): 276–279. doi:10.1093/jhmas/jrn014.
- Didgeon JA (May 1963). "Development of Smallpox Vaccine in England in the Eighteenth and Nineteenth Centuries". British Medical Journal. 1 (5342): 1367–1372. doi:10.1136/bmj.1.5342.1367. PMC 2124036. PMID 20789814.
- Louten, Jennifer (2016). Essential Human Virology. Academic Press. pp. 134–135. ISBN 9780128011713.
- Baarda BI, Sikora AE (2015). "Proteomics of Neisseria gonorrhoeae: the treasure hunt for countermeasures against an old disease". Frontiers in Microbiology. 6: 1190. doi:10.3389/fmicb.2015.01190. PMC 4620152. PMID 26579097; Access provided by the University of Pittsburgh.CS1 maint: postscript (link)
- Alarcon JB, Waine GW, McManus DP (1999). "DNA Vaccines: Technology and Application as Anti-parasite and Anti-microbial Agents". Advances in Parasitology Volume 42. Advances in Parasitology. 42. pp. 343–410. doi:10.1016/S0065-308X(08)60152-9. ISBN 9780120317424. PMID 10050276.
- Robinson HL, Pertmer TM (2000). DNA vaccines for viral infections: basic studies and applications. Advances in Virus Research. 55. pp. 1–74. doi:10.1016/S0065-3527(00)55001-5. ISBN 9780120398553. PMID 11050940.
- Naftalis, Kramer Levin; Royzman, Frankel LLP-Irena; Pineda, ré (30 November 2020). "Third-Generation Vaccines Take Center Stage in Battle Against COVID-19 | Lexology". www.lexology.com. Retrieved 24 January 2021.
- Regalado, Antonio. "The U.S. government has begun testing its first Zika vaccine in humans". Retrieved 2016-08-06.
- Chen Y, Wang S, Lu S (February 2014). "DNA Immunization for HIV Vaccine Development". Vaccines. 2 (1): 138–159. doi:10.3390/vaccines2010138. PMC 4494200. PMID 26344472.
- "Katalin Karikó and Drew Weissman Awarded Horwitz Prize for Pioneering Research on COVID-19 Vaccines". Columbia University Irving Medical Center. 2021-08-12. Retrieved 2021-09-07.
- Staff (28 March 2013). "Safer vaccine created without virus". The Japan Times. Agence France-Presse – Jiji Press. Archived from the original on 30 March 2013. Retrieved 2013-03-28.
- Spohn G, Bachmann MF (February 2008). "Exploiting viral properties for the rational design of modern vaccines". Expert Review of Vaccines. 7 (1): 43–54. doi:10.1586/14760518.104.22.168. PMID 18251693. S2CID 40130001.
- Samuelsson O, Herlitz H (March 2008). "Vaccination against high blood pressure: a new strategy". Lancet. 371 (9615): 788–789. doi:10.1016/S0140-6736(08)60355-4. PMID 18328909. S2CID 38323966.
- Poland GA, Jacobson RM, Ovsyannikova IG (May 2009). "Trends affecting the future of vaccine development and delivery: the role of demographics, regulatory science, the anti-vaccine movement, and vaccinomics". Vaccine. 27 (25–26): 3240–3244. doi:10.1016/j.vaccine.2009.01.069. PMC 2693340. PMID 19200833.
- Sala F, Manuela Rigano M, Barbante A, Basso B, Walmsley AM, Castiglione S (January 2003). "Vaccine antigen production in transgenic plants: strategies, gene constructs and perspectives". Vaccine. 21 (7–8): 803–808. doi:10.1016/s0264-410x(02)00603-5. PMID 12531364.
- Kumar GB, Ganapathi TR, Revathi CJ, Srinivas L, Bapat VA (October 2005). "Expression of hepatitis B surface antigen in transgenic banana plants". Planta. 222 (3): 484–493. doi:10.1007/s00425-005-1556-y. PMID 15918027. S2CID 23987319.
- Ostachuk AI, Chiavenna SM, Gómez C, Pecora A, Pérez-Filgueira MD, Escribano JM, Ardila F, Dus MJ, Santos AW (2009). "Expression of a ScFv–E2T fusion protein in CHO-K1 cells and alfalfa transgenic plants for the selective directioning to antigen presenting cells". Veterinary Immunology and Immunopathology. 128 (1): 315. doi:10.1016/j.vetimm.2008.10.224. Archived from the original on 2018-05-01.
- Peréz Aguirreburualde MS, Gómez MC, Ostachuk A, Wolman F, Albanesi G, Pecora A, Odeon A, Ardila F, Escribano JM, Dus Santos MJ, Wigdorovitz A (February 2013). "Efficacy of a BVDV subunit vaccine produced in alfalfa transgenic plants". Veterinary Immunology and Immunopathology. 151 (3–4): 315–324. doi:10.1016/j.vetimm.2012.12.004. PMID 23291101.
|Wikiquote has quotations related to: Vaccines|
|Modern Vaccine and Adjuvant Production and Characterization, Genetic Engineering & Biotechnology News|
- Vaccines and Antisera at Curlie
- WHO Vaccine preventable diseases and immunization
- World Health Organization position papers on vaccines
- The History of Vaccines, from the College of Physicians of Philadelphia
- This website was highlighted by Genetic Engineering & Biotechnology News in its "Best of the Web" section in January 2015. See: "The History of Vaccines". Best of the Web. Genetic Engineering & Biotechnology News. 35 (2). 15 January 2015. p. 38.